Arena gets 10/22 PDUFA date for lorcaserin

Arena Pharmaceuticals should know by October 22 if its closely-watched obesity drug--lorcaserin--will win approval by the FDA. The drug is widely viewed as a likely blockbuster if it breaks into the huge market for weight-loss drugs. "With an October PDUFA date for the lorcaserin NDA, we are another step closer to our goal of improving the treatment of obesity. We believe that lorcaserin, if approved, will be well positioned as first-line therapy to help patients achieve sustainable weight loss in a well-tolerated manner," says CEO Jack Lief. A total of 8,576 patients have been enrolled in 18 clinical trials for the therapy. Arena release

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.